TAK-285

Min.Order / FOB Price:Get Latest Price

0	Negotiable

Min.Order :0
Purity: 95%

Keywords

TAK285 TAK 285

Quick Details

Appearance:
Application:For research use only.
PackAge:
ProductionCapacity:
Storage:
Transportation:

Superiority:

We provide customized and high-quality TAK-285 product for your project.

Details:

TAK-285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK-285 is currently being developed by Takeda. TAK-285 was found to be well tolerate in Phase I trials. Absorption of TAK-285 was rapid after oral dosing, and plasma exposure at steady-state increased in a dose-proportional fashion for doses ranging from 50 to 300?mg b.i.d. A partial response was observed for one patient with parotid cancer who received 300?mg b.i.d. The toxicity profile and PK properties of oral TAK-285 warrant further evaluation.

View All